Biomea Fusion said key clinical milestones for its diabetes and obesity pipeline are expected in 2027. The update came with Q3 2026 results and follows earlier

BWB News TV • 2026-11-10 23:22 UTC • By Billy Odell Tucker-Robinson

Biomea Fusion said key clinical milestones for its diabetes and obesity pipeline are expected in 2027. The update came with Q3 2026 results and follows earlier Phase I data for oral GLP-1 candidate BMF-650.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly